PierianDx Accelerates Precision Medicine with Fully Integrated Workflow and Interpretation Solution Supporting Illumina TruSight Tumor 170
PierianDx, the forerunner in clinical genomic analysis, interpretation and reporting, announced today it has launched a complete technology and medical interpretation solution to support Illumina’s TruSight Tumor 170 (TST170). PierianDx will feature TST170 in an upcoming webinar October 12, 2017, at 1 pm EST hosted by GenomeWeb.
The webinar, entitled Precision Oncology Roundtable: Ask the Experts About NGS-based Tumor Profiling, will be an interactive discussion on the adoption of Illumina’s commercial gene panel for tumor profiling at several leading US cancer centers. The panel will include: Dr. Gregory Tsongalis from Dartmouth-Hitchcock, Dr. Anthony Magliocco from Moffitt Cancer Center, Dr. Ravindra Kolhe from Medical College of Georgia at Augusta University, and Dr. Rakesh Nagarajan from PierianDx.
“Our customers are demanding a comprehensive solid tumor assay that is cost effective,” said PierianDx CEO Ted Briscoe. “By combining the power of Illumina’s TST170 assay with PierianDx’s integrated workflow and interpretation services, we are able to offer our customers a complete solution.”
The TST170 next-generation sequencing-based assay targets single nucleotide variants, indels, gene amplifications, gene fusions, splice variants, mRNA expression, and mRNA isoform detection found in 170 cancer-related genes. PierianDx’s TST170 solution also calculates metrics such as tumor mutation burden (TMB) and determines evidence for microsatellite instability (MSI).
PierianDx has worked closely with its customers and Illumina to enable TST170 by integrating the assay into the Clinical Genomicist Workspace (CGW) workflow and supporting customers with validation and interpretation services. PierianDx’s complete TST170 solution will benefit from the millions of biomedical findings contained in PierianDx’s proprietary knowledgebase, which is constantly updated with the latest medical literature, guidelines, clinical trials and shared interpretations.
For more information about TST170 or to register for the webinar, go to:
PierianDx enables clinical labs to deliver patient-specific diagnosis and treatments based on an individual’s DNA for cancers and hereditary diseases. Utilizing PierianDx’s comprehensive and integrated “one space” NGS workflow and analysis solution, Clinical Genomicist Workspace (CGW), clinical labs create more streamlined and accurate analysis, interpretation, and reporting needed to accelerate their personalized medicine programs.